Wake Forest University Health Sciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).
Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.
Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.
Top-decile sponsor footprint
Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,140 total, page 23 of 23
Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer
NCT00064298
Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases
NCT00049361
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
NCT00079092
Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer
NCT00337233
Zinc Supplements in Lowering Cadmium Levels in Smokers
NCT00376987
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00310154
Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix
NCT00084890
Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer
NCT00345813
Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer
NCT00899860
Cholecalciferol in Treating Patients With Myelodysplastic Syndrome
NCT00068276
Aspirin Use and Postoperative Bleeding From Dental Extractions in a Healthy Population
NCT00405613
Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment
NCT00072579
Bacteria Entering the Blood Stream From Tooth Extractions and Tooth Brushing
NCT00454285
Diet, Exercise, Metabolism, and Obesity in Older Women
NCT00664729
Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer
NCT00310076
Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia
NCT00082940
Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors
NCT00311597
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
NCT00031798
Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
NCT00028938
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00025272
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
NCT00025168
Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00025285
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
NCT00070161
Look AHEAD: Action for Health in Diabetes
NCT00017953
Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas
NCT00010166
Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer
NCT00006799
DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
NCT00003840
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
NCT00031785
Gemcitabine in Treating Patients With Advanced Colorectal Cancer
NCT00007943
A Study of Immediate and Delayed Closure of Type II and IIIa Open Tibia Fractures
NCT01315392
Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder
NCT00489515
Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer
NCT00766454
Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium
NCT00310011
Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
NCT00003202
The Arthritis, Diet, and Activity Promotion Trial
NCT00979043
Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery
NCT00015886
Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer
NCT00002942
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
NCT00002865
The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.
NCT03097120
Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer
NCT00002943
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 96 |
| Phase 2 | 143 |
| Phase 3 | 31 |
| Phase 4 | 80 |
Therapeutic Areas
What is open in the Wake Forest University Health Sciences pipeline
174 recruiting of 1,140 indexed (15% open); 724 completed (64%).
Phase mix: 111 late (III/IV) vs 239 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Wake Forest University Health Sciences: open-pipeline peers nationwide
Peers matched on 1,140 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,140 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
- University of Florida · 1,106 trials · 15% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Baylor University · 15% recruiting · 33 trials
- Cornell University · 15% recruiting · 66 trials
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
Related
What to do with this Wake Forest University Health Sciences page
1,140 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University Health Sciences or any single study.
- 174 of Wake Forest University Health Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Wake Forest University Health Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Wake Forest University Health Sciences pipeline card: 1,140 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.